This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
REGNNegative Net Change SNYNegative Net Change GILDNegative Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026?
by Ahan Chakraborty
Novo Nordisk's FDA-approved Wegovy pill marks the first oral GLP-1 weight loss therapy, aiming to revive momentum and reshape competition in 2026.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
by Ekta Bagri
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
REGNNegative Net Change ABBVNegative Net Change ANIPPositive Net Change
biotechnology biotechs medical pharmaceuticals
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?
by Zacks Equity Research
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains
by Zacks Equity Research
Vanda stock jumps after FDA approves tradipitant as Nereus for motion sickness, marking the first new therapy in over 40 years and boosting investor optimism.
NVOPositive Net Change VNDANegative Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can BMY's Growth Portfolio Drive Top-Line Expansion in 2026?
by Ekta Bagri
Bristol Myers Squibb's growth drugs rose 17% in the first nine months of 2025, helping offset a 16% legacy drug sales decline.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bear of the Day: Azenta (AZTA)
by Shaun Pruitt
2025 was another turbulent year for Azenta (AZTA) stock, which fell more than 30% as the medical solutions provider struggled with ongoing sales weakness.
AZTAPositive Net Change
biotechnology earnings gene-therapy medical
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
by Ekta Bagri
AMGN edges out its rival with stronger growth estimates, a broad portfolio boost from Horizon, and momentum from key drugs like Repatha and Tezspire.
BMYNegative Net Change PFENegative Net Change MRKPositive Net Change AMGNNegative Net Change
biotechnology biotechs dividend-yield medical pharmaceuticals
Tilly's (TLYS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
TLYSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
3 Dividend-Paying Pharma Stocks Worth Watching for Steady 2026 Gains
by Sundeep Ganoria
Three dividend-paying pharma stocks stand out for steady 2026 gains as innovation, pricing deals and resilient drug demand support returns.
JNJNegative Net Change MRKPositive Net Change ABBVNegative Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals vaccines
3 Biotech Stocks With Major 2026 Catalysts
by Ekta Bagri
Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts lined up for 2026.
VNDANegative Net Change DNLINegative Net Change NUVLNegative Net Change
biotechnology biotechs medical pharmaceuticals
Mitek Systems (MITK)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
MITKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Company News for Dec 26, 2025
by Zacks Equity Research
Companies In The News Are: NVDA, NKE, AAPL, DVAX, SNY, INTC.
INTCNegative Net Change SNYNegative Net Change AAPLNegative Net Change DVAXPositive Net Change NKEPositive Net Change NVDANegative Net Change
biotechnology pharmaceuticals retail semiconductor
Soft Weekly Jobless Claims Data
by Zacks Equity Research
Soft Weekly Jobless Claims Data.
SNYNegative Net Change DVAXPositive Net Change ADPPositive Net Change
biotechnology business-services pharmaceuticals
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
by Zacks Equity Research
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
SNYNegative Net Change DVAXPositive Net Change CRMDPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals vaccines
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
XFORNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Midland States Bancorp (MSBI) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
MSBIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
by Ekta Bagri
BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
BMYNegative Net Change JNJNegative Net Change PFENegative Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
by Zacks Equity Research
NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.
NVOPositive Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
by Ahan Chakraborty
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
by Ahan Chakraborty
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
IONSNegative Net Change KODNegative Net Change MNPRNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Cactus, Inc. (WHD)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
WHDPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
O-I Glass (OI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
OIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
EverQuote (EVER) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
EVERNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up
by Zacks Equity Research
CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.
BMYNegative Net Change FOLDNegative Net Change CYTKNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals